GlycoMimetics Inc. [NASDAQ: GLYC] stock went on a downward path that fall over -9.75% on Tuesday, amounting to a one-week price decrease of less than -7.43%. The company report on March 2, 2021 that GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020.
Second half of 2021 remains the target for completion of enrollment of the GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) .
Enrollment in 2021 is expected to support a planned interim analysis based on event-free survival in the National Cancer Institute’s (NCI) registration trial evaluating uproleselan in newly diagnosed AML patients over the age of 60 years and fit for chemotherapy.
Over the last 12 months, GLYC stock dropped by -7.69%. The average equity rating for GLYC stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $159.67 million, with 47.51 million shares outstanding and 46.60 million shares in the current float. Compared to the average trading volume of 797.43K shares, GLYC stock reached a trading volume of 1963191 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on GlycoMimetics Inc. [GLYC]:
ROTH Capital have made an estimate for GlycoMimetics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 14, 2019. While these analysts kept the previous recommendation, SunTrust raised their target price from $23 to $5. The new note on the price target was released on August 05, 2019, representing the official price target for GlycoMimetics Inc. stock. Previously, the target price had yet another drop from $20 to $6, while Piper Jaffray kept a Neutral rating on GLYC stock.
The Average True Range (ATR) for GlycoMimetics Inc. is set at 0.25, with the Price to Sales ratio for GLYC stock in the period of the last 12 months amounting to 15.97. The Price to Book ratio for the last quarter was 1.11, with the Price to Cash per share for the same quarter was set at 2.90.
GLYC Stock Performance Analysis:
GlycoMimetics Inc. [GLYC] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.43. With this latest performance, GLYC shares dropped by -10.74% in over the last four-week period, additionally sinking by -14.06% over the last 6 months – not to mention a drop of -7.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GLYC stock in for the last two-week period is set at 34.35, with the RSI for the last a single of trading hit 30.56, and the three-weeks RSI is set at 38.00 for GlycoMimetics Inc. [GLYC]. The present Moving Average for the last 50 days of trading for this stock 3.82, while it was recorded at 3.41 for the last single week of trading, and 3.59 for the last 200 days.
Insight into GlycoMimetics Inc. Fundamentals:
Return on Total Capital for GLYC is now -33.80, given the latest momentum, and Return on Invested Capital for the company is -31.94. Return on Equity for this stock declined to -32.19, with Return on Assets sitting at -30.25. When it comes to the capital structure of this company, GlycoMimetics Inc. [GLYC] has a Total Debt to Total Equity ratio set at 2.35. Additionally, GLYC Total Debt to Total Capital is recorded at 2.30, with Total Debt to Total Assets ending up at 2.16. Long-Term Debt to Equity for the company is recorded at 1.83, with the Long-Term Debt to Total Capital now at 1.79.
Reflecting on the efficiency of the workforce at the company, GlycoMimetics Inc. [GLYC] managed to generate an average of -$1,015,648 per employee.GlycoMimetics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 14.80 and a Current Ratio set at 14.80.
GLYC Stock EPS
With the latest financial reports released by the company, GlycoMimetics Inc. posted -0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GLYC.
GlycoMimetics Inc. [GLYC] Insider Position Details
There are presently around $125 million, or 84.70% of GLYC stock, in the hands of institutional investors. The top three institutional holders of GLYC stocks are: BVF INC/IL with ownership of 9,544,262, which is approximately 31.749% of the company’s market cap and around 2.10% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 9,089,041 shares of the stock with an approximate value of $29.45 million in GLYC stocks shares; and BLACKROCK INC., currently with $8.48 million in GLYC stock with ownership of nearly -10.85% of the company’s market capitalization.
Positions in GlycoMimetics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 53 institutional holders increased their position in GlycoMimetics Inc. [NASDAQ:GLYC] by around 7,940,973 shares. Additionally, 34 investors decreased positions by around 8,909,072 shares, while 16 investors held positions by with 21,882,739 shares. The mentioned changes placed institutional holdings at 38,732,784 shares, according to the latest SEC report filing. GLYC stock had 22 new institutional investments in for a total of 2,008,696 shares, while 12 institutional investors sold positions of 7,628,034 shares during the same period.